EC Cardiology

Editorial Volume 6 Issue 8 - 2019

Cardiac Implantable Electronic Devices (CIEDs) Infection, What To Do?

Syed Haseeb Raza Naqvi1 and Han Naung Tun2*

1CPE Institute of Cardiology, Multan, Punjab, Pakistan

2Clinical and Research Working Groups, European Society of Cardiology, Sophia Antipolis, France

*Corresponding Author: Han Naung Tun, Clinical and Research Working Groups, European Society of Cardiology, Sophia Antipolis, France.
Received: June 07, 2019; Published: July 09, 2019




Cardiac Implantable Electronic Devices (CIEDs) which include permanent pacemaker (PPM) or implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy (CRT), have turned out to be very useful treatment of current era. In these days, an ICD is used not only to save survivors of cardiac arrest, but it also came out to be the first-line primary prevention to save patients with severe cardiac dysfunction. Furthermore, the advanced medical technology has resulted in resynchronization therapy, leading to higher rate of device implantation [1,2]. As the device implantation has increased, the CIED infection has also increased leading to increase in fatal and serious complications [3-7]. Prutkin., et al. reported that a total of 3390 (1.7%) out of 200,909 implanted ICDs, when followed for first six months, developed infection of device [6]. Other literature revealed a similar rate of CIED infection (0.7 - 2.2%) [5,8,9]. It is difficult to manage the infection of CIEDs, requiring good knowledge and special efforts by the doctors. CIED infections are needed to be treated aggressively, including appropriate antibiotics and complete removal of the infected device [5,10]. Prompt and complete device removal in combination with antimicrobial therapy is also endorsed by consensus reports and statements [11-13].

  1. Goldberger Z and Lampert R. “Implantable cardioverter defibrillators: Expanding indications and technologies”. Journal of the American Medical Association 7 (2006): 809-818.
  2. Uslan DZ., et al. “Permanent pacemaker and implantable cardioverter defibrillator infection: a population based study”. Archives of internal medicine7 (2007): 669-675.
  3. Uslan DZ and Baddour LM. “Cardiac device infections: getting to the heart of the matter”. Current Opinion in Infectious Diseases4 (2006): 345-348.
  4. Voigt A., et al. “Rising rates of cardiac rhythm management device infections in the United States: 1996 through 2003”. Journal of the American College of Cardiology3 (2006): 590-591.
  5. Margey R., et al. “Contemporary management of and outcomes from cardiac device related infections”. Europace1 (2010): 64-70.
  6. Prutkin JM., et al. “Rates of and factors associated with infection in 2009 09 medicare implantable cardioverter defibrillator implants:results from the national cardiovascular data registry”. Circulation 130 (2014): 1037-1043.
  7. Alter P., et al. “Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients”. Pacing and Clinical Electrophysiology9 (2005): 926-932.
  8. Nery PB., et al. “Device related infection among patients with pacemakers and implantable defibrillators: incidence, risk factors, and consequences”. Journal of Cardiovascular Electrophysiology7 (2010): 786-790.
  9. Lekkerkerker JC., et al. “Risk factors and time delay associated with cardiac device infections: leiden device registry”. Heart9 (2009): 715-720.
  10. Le KY., et al. “Impact of timing of device removal on mortality in patients with cardiovascular implantable electronic device infections”. Heart Rhythm11 (2011): 1678-1685.
  11. Baddour LM., et al. “Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association”. Circulation3 (2010): 458-477.
  12. Baddour LM., et al. “Nonvalvular cardiovascular device-related infections”. Circulation16 (2003): 2015-2031.
  13. Wilkoff BL., et al. “Transvenous lead extraction: Heart Rhythm Society expert consensus on facilities, training, indications, and patient management: this document was endorsed by the American Heart Association (AHA)”. Heart Rhythm7 (2009): 1085-1104.
  14. Chua JD., et al. “Diagnosis and management of infections involving implantable electrophysiologic cardiac devices”. Annals of Internal Medicine8 (2000): 604-608.
  15. Welch M., et al. “Variability in clinical features of early versus late cardiovascular implantable electronic device pocket infections”. Pacing and Clinical Electrophysiology8 (2014): 955-962.
  16. Sohail MR., et al. “Management and outcome of permanent pacemaker and implantable cardioverter defibrillator infections”. Journal of the American College of Cardiology18 (2007): 1851-1859.
  17. Nof E and Epstein LM. “Complications of cardiac implants: handling device infections”. European Heart Journal3 (2013): 229-235.
  18. Garcia-Rinaldi R., et al. “The exposed cardiac pacemaker. Treatment by sub fascial pocket relocation”. The Journal of Thoracic and Cardiovascular Surgery1 (1985): 136-141.
  19. Hurst LN., et al. “The salvage of infected cardiac pacemaker pockets using a closed irrigation system”. Pacing and Clinical Electrophysiology6 (1986): 785-792.
  20. Baddour LM. “Long-term suppressive antimicrobial therapy for intravascular device-related infections”. The American Journal of the Medical Sciences4 (2001): 209-212.
  21. Segreti J., et al. “Prolonged suppressive antibiotic therapy for infected orthopedic prostheses”. Clinical Infectious Diseases4 (1998): 711-713.
  22. Ortler M., et al. “Deep wound infection after vagus nerve stimulator implantation: treatment without removal of the device”. Epilepsia1 (2001): 133-135.
  23. Bongiorni MG., et al. “Microbiology of cardiac implantable electronic device infections”. Europace 9 (2012): 1334-1339.
  24. Muers MF., et al. “Prophylactic antibiotics for cardiac pacemaker implantation: a prospective trial”. British Heart Journal5 (1981): 539-544.
  25. Bluhm G., et al. “Antibiotic prophylaxis in pacemaker surgery: a prospective study”. Scandinavian Journal of Thoracic and Cardiovascular Surgery3 (1984): 227-234.
  26. Ramsdale DR., et al. “Antibiotic prophylaxis for pacemaker implantation: a prospective randomized trial”. Pacing and Clinical Electro physiology5 (1984): 844-849.
  27. Bluhm G., et al. “Antibiotic prophylaxis in pacemaker surgery: a prospective double blind trial with systemic administration of antibiotic versus placebo at implantation of cardiac pacemakers”. Pacing and Clinical Electrophysiology5 (1986): 720-726.
  28. Glieca F., et al. “The role of antibiotic prophylaxis in the implantation of pacemakers”. Minerva Cardioangiologica10 (1987): 549-552.
  29. Luninghake F., et al. “Antibiotic prophylaxis for pacemaker implantation: a prospective study”. Pacing and Clinical Electrophysiology 16 (1993): 1138.
  30. Mounsey JP., et al. “Antibiotic prophylaxis in permanent pacemaker implantation: a prospective randomized trial”. British Heart Journal4 (1994): 339-343.
  31. Da Costa A., et al. “Antibiotic prophylaxis for permanent pacemaker implantation: a meta-analysis”. Circulation 97.18 (1998): 1796-1801.
  32. Bloom HL., et al. “Implantation success and infection in cardiovascular implantable electronic device procedures utilizing an antibacterial envelope”. Pacing and Clinical Electrophysiology2 (2011): 133-142.
  33. Kolek MJ., et al. “Use of an antibacterial envelope is associated with reduced cardiac implantable electronic device infections in high-risk patients”. Pacing and Clinical Electrophysiology3 (2013): 354-361.
  34. Mittal S., et al. “Cardiac implantable electronic device infections: incidence, risk factors, and the effect of the AigisRx antibacterial envelope”. Heart Rhythm4 (2014): 595-601.
  35. Kolek MJ and Ellis CR. “New approaches to decrease cardiac implantable electronic device infections”. Cardiac Electrophysiology Clinics2 (2014): 279-284.
  36. Ahsan SY., et al. “A simple infection-control protocol to reduce serious cardiac device infections”. Europace10 (2014): 1482-1489.
  37. Polyzos KA., et al. “Risk factors for cardiac implantable electronic device infection: A systematic review and meta-analysis”. Europace5 (2015): 767-777.
  38. Tarakji KG., et al. “Cardiac Implantable Electronic Device Infection in Patients at Risk”. Arrhythmia and Electrophysiology Review1 (2016): 65-71.
  39. Steenmeijer R., et al. “Characteristics of cardiac device infections in the Isala hospital a large volume tertiary care cardiology centre”. Netherlands Heart Journal3 (2016): 199-203.
  40. Klug D., et al. “Risk Factors Related to Infections of Implanted Pacemakers”. Circulation12 (2007): 1349-1355.
  41. Johansen JB., et al. “Infection after pacemaker implantation: Infection rates and risk factors associated with infection in a population based cohort study of 46299 consecutive patients”. European Heart Journal8 (2011): 991-998.
  42. Sohail MR., et al. “Risk Factor Analysis of Permanent Pacemaker Infection”. Clinical Infectious Diseases2 (2007): 166-173.
  43. Lin YS., et al. “Impact of pacemaker lead characteristics on pacemaker related infection and heart perforation: A nationwide population-based cohort study”. PLoS One6 (2015): e0128320.
  44. Shariff N., et al. “Health and economic outcomes associated with use of an antimiocrobial envelope as a standard of care of cardiac implantable electronic device implantation”. Journal of Cardiovascular Electrophysiology7 (2015): 783-789.
  45. Caldero´ n-Parra J., et al. “Proposal for a Novel Score to Determine the Risk of Cardiac Implantable Electronic Device Infection”. Revista Española de Cardiología (2018).

Syed Haseeb Raza Naqvi and Han Naung Tun. "Cardiac Implantable Electronic Devices (CIEDs) Infection, What To Do?." EC Cardiology 6.8 (2019): 694-698.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net